

FIG. 1





FIG. 2



5

FIG. 3

Challenges of Alternate ADC Protein Engineering and Chemistry





FIG. 4


Potential "Best-in-class" Site-specific ADC's



5

FIG. 5


BH3973: Improved Plasma Stability Over Adcetris®



- ◊ ADC toxicity/tolerability directly relates to free payload
- Enhanced stability reduces free payload, and potentially allows for higher drug concentration at targeted tumor site for same tolerability

FIG. 6

Adcetris® and BH3973 Demonstrate Comparable PK



- BH3973 half-life 7-8 days across all doses
- Adcetris® half-life 5-6 days across all doses

5

FIG. 7

BH3973: Demonstrates Potential for Superior Efficacy to Adcetris®





FIG. 8

BH3973: Improves Survival in Preclinical Model Compared to Adcetris® With Half the Payload





FIG. 9

Single Dose 14-Day Study of BH-3973 by IV Administration in NHPs



5

